A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated on behalf of investors who purchased the company’s securities between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges the company made misleading statements and omissions about the clinical evidence and regulatory prospects for its relacorilant drug application, including overstating trial support and downplaying FDA concerns. Investors seeking to be appointed lead plaintiff must move by April 21, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603021651PRIMZONEFULLFEED9664355) on March 02, 2026, and is solely responsible for the information contained therein.